Arthneeti
Archean ChemicalQ4 FY23

Archean Chemical Q4 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹470P/E: 60.0Market Cap: ₹5.8K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 1

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 1
  • The company aims to double its overall top line in the next 2-3 years, with sales expected to reach around ₹600-700 crores post-Greenfield expansion.
  • Greenfield expansion has an asset turnover of 3x, supporting expected sales growth.
  • Bromine volumes for FY24 are expected to grow more than high single digits, with increasing domestic volumes.
  • Sulphate of potash production (~8,000 MT) is planned to be sold in FY24, with production to pick up in the second half of the year.
  • Salt volume growth is expected to be in the more than single-digit range for FY24, supported by additional capacity expansions.
  • The company plans to utilize 40% of bromine production captively in downstream operations at peak capacity.
  • Margins are targeted to be maintained at 40-45% despite market volatility.

See what Archean Chemical management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • There is no mention of any current or planned new fundraising through debt or equity in the transcript.
  • The company has redeemed all its Non-Convertible Debentures (NCDs) using IPO proceeds, resulting in a net debt-to-equity ratio of zero as of FY23.
  • The focus appears to be on internal funding through IPO proceeds and operational cash flows for expansions.
  • The company is investing in capacity expansions (Greenfield project, salt washing lines) funded through its resources without indication of external fundraising plans.
  • The lease renewal process at Rann of Kutch (a key asset) is ongoing but not linked to fundraising.
  • Management did not indicate any plans for new debt or equity issuance during the earnings call.

See what Archean Chemical management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Archean Chemical Industries is undertaking a Greenfield expansion at Jhagadia focused on bromine performance derivatives such as flame retardants, clear brine fluids, and bromine catalyst.
  • This Greenfield project, with an estimated capex of Rs. 250 crores, is on track and expected to commence production by the end of FY24.
  • An additional capacity expansion for industrial salt washing lines is planned, aiming to increase capacity by another 250 tons per hour, expected in the latter part of FY24.
  • The company continues to invest in expanding its capacity and product portfolio, targeting downstream bromine derivatives.
  • These expansions aim to double or triple sales in the next two to three years and maintain robust operating margins.
  • The capex is focused on strengthening the company’s position in higher-margin downstream products.

Track Archean Chemical — get its next earnings analysis in your feed

Margin guidance

Category 3
  • The company aims to at least double its top-line over the next 2-3 years post Greenfield expansion, targeting sales of ₹600-700 crores from the new plant.
  • Operating Profit Margins (OPMs) are expected to maintain or possibly improve, especially with downstream bromine derivatives projected at 25%-30% margin.
  • FY23 saw 41% growth in EBITDA with margins around 46%; management targets to sustain margins in the 40%-45% range going forward.
  • Net profit doubled in FY23, driven by better realizations and reduced interest costs; growth momentum is expected to continue.
  • Sulphate of potash production and sales will increase from FY24 onwards, supporting earnings growth.
  • Salt business volume and pricing are expected to grow steadily with capacity expansion benefits kicking in FY25.
  • Overall, robust cost control, pricing power, and capacity expansions are expected to drive strong earnings and EPS growth.

Order book

The transcript from the provided pages does not specifically mention current or expected orderbook or pending orders for Archean Chemical Industries Limited. However, related insights include: - Approximately half of the bromine volumes are under long-term contracts (around one year) and half are spot or shorter-term contracts. - About half of the industrial salt volumes are contracted for the next two years. - The company is confident in volume growth for salt with more than single-digit increase expected next year. - The Sulphate of potash production of about 8,000 MT is planned to be sold in FY24. - Derivative products from the new Greenfield plant are in initial marketing stages, expected to gather momentum later in the year. - Long-term and spot contracts help manage price volatility and maintain realizations. No explicit orderbook or pending order values are cited in the available transcript excerpts.

How does Archean Chemical rank vs peers in Chemicals & Petrochemicals?

Pro feature
ThisArchean Chemical
Rev 1Mar 3
See where Archean Chemical sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Archean Chemical rank in Chemicals & Petrochemicals?

Compare Archean Chemical against every Chemicals & Petrochemicals company (Q4 FY23) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

Continue your research

What Archean Chemical's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

  • Sudarshan Chemical Industries Ltd (Q1 FY27)

    The net debt has already been reduced significantly from Rs.922 Crores at acquisition to Rs.531 Crores. Key concall takeaways from Sudarshan Chemical…

  • Indo Borax & Ch. (Q1 FY27)

    250-260 crores in FY27 with about 20% EBITDA margin, growing at 11-12% annually in absolute terms. Key concall takeaways from Indo Borax & Chemicals Ltd's Q1…

  • SRF (Q1 FY27)

    Chemicals business is guided for 15-20% growth in FY27, with a strong Q1 performance positioning the company to possibly hit the higher end of this range (Page…

  • Deepak Fertilis. (Q1 FY27)

    Long-term demand-supply balance looks stable with 6-7% market growth, supporting sustained revenues despite new capacity additions. Key concall takeaways from…

Compare:vs Solar Industriesvs Pidilite Inds.vs SRF

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →